


Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (withdrawn-original) A method of providing neuroprotection in a patient following a cerebrovascular ischemic event comprising providing a therapeutically effective amount of a compound of the formula



wherein:

X is N, CH

n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof; with the proviso that when n is 1, X is not N.

2. (withdrawn-original) The method of Claim 1 wherein R' is methyl.
3. (withdrawn-original) The method of Claim 1 wherein R is methyl or ethyl.
4. (withdrawn-original) The method of Claim 1 wherein X is N.
5. (withdrawn-original) The method of Claim 1 wherein X is CH.
6. (withdrawn-original) The method of Claim 1 wherein the compound is:  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[3-(4-ethyl-1-piperazinyl)propoxy]- 6-methoxy-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[2-(4-ethyl-1-piperazinyl)ethoxy]- 6-methoxy-3-quinolinecarbonitrile;


4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile; or  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; and pharmaceutically acceptable salts thereof.

7. (withdrawn-original) The method of Claim 1 wherein compound is administered between about 6 to about 24 hours after the ischemic event.
8. (withdrawn-original) The method of Claim 1 wherein the therapeutically effective amount is from about 1 mg/kg to about 30 mg/kg.
9. (withdrawn-original) The method of Claim 1 comprising administering compound of Formula I intravenously.
10. (withdrawn-original) The method of Claim 1 wherein the patient is a human.
11. (withdrawn-original) The method of Claim 1 wherein the ischemic event is transient.
12. (withdrawn-original) The method of Claim 1 wherein the ischemic event is acute.

13. (withdrawn-original) The method of Claim 1 wherein the ischemic event is stroke, head trauma, spinal trauma, general anoxia, or hypoxia.

14. (withdrawn-original) The method of Claim 1 wherein the ischemic event occurs during cranial hemorrhage, perinatal asphyxia, cardiac arrest or status epilepticus.

15. (withdrawn-original) A method of inhibiting neurological deficits in a patient following a cerebrovascular ischemic event comprising providing a therapeutically effective amount of a compound of the formula



wherein:

X is N, CH

n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof; with the proviso that when n is 1, X is not N.

16. (withdrawn-original) The method of Claim 15 wherein R' is methyl.

17. (withdrawn-original) The method of Claim 15 wherein R is methyl or ethyl.

18. (withdrawn-original) The method of Claim 15 wherein X is N.

19. (withdrawn-original) The method of Claim 15 wherein X is CH.

20. (withdrawn-original) The method of Claim 15 wherein the compound is:


4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[3-(4-ethyl-1-piperazinyl)propoxy]- 6-methoxy-3-quinolinecarbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile; or  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; and pharmaceutically acceptable salts thereof.

21. (withdrawn-original) The method of Claim 15 wherein compound is administered between about 6 to about 24 hours after the ischemic event.
22. (withdrawn-original) The method of Claim 15 wherein the therapeutically effective amount is from about 1 mg/kg to about 30 mg/kg.
23. (withdrawn-original) The method of Claim 15 comprising administering compound of Formula I intravenously.
24. (withdrawn-original) The method of Claim 15 wherein the patient is a human.

25. (withdrawn-original) The method of Claim 15 wherein the ischemic event is transient.
26. (withdrawn-original) The method of Claim 15 wherein the ischemic event is acute.
27. (withdrawn-original) The method of Claim 15 wherein the ischemic event is stroke, head trauma, spinal trauma, general anoxia, or hypoxia.
28. (withdrawn-original) The method of Claim 15 wherein the ischemic event occurs during cranial hemorrhage, perinatal asphyxia, cardiac arrest or status epilepticus.
29. (withdrawn-original) A method of reducing infarct volumes in a patient following a cerebrovascular ischemic event comprising administering a therapeutically effective amount of a compound of the formula



wherein:

X is N, CH

n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof; with the proviso that when n is 1, X is not N.


30. (withdrawn-original) The method of Claim 29 wherein R' is methyl.
31. (withdrawn-original) The method of Claim 29 wherein R is methyl or ethyl.
32. (withdrawn-original) The method of Claim 29 wherein X is N.
33. (withdrawn-original) The method of Claim 29 wherein X is CH.
34. (withdrawn-original) The method of Claim 29 wherein the compound is:

4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[3-(4-ethyl-1-piperazinyl)propoxy]- 6-methoxy-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[2-(4-ethyl-1-piperazinyl)ethoxy]- 6-methoxy-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile; or  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile; and pharmaceutically acceptable salts thereof.

35. (withdrawn-original) The method of Claim 29 wherein compound is administered between about 6 to about 24 hours after the ischemic event.

36. (withdrawn-original) The method of Claim 29 wherein the therapeutically effective amount is from about 1 mg/kg to about 30 mg/kg.

37. (withdrawn-original) The method of Claim 29 comprising administering compound of Formula I intravenously.
38. (withdrawn-original) The method of Claim 29 wherein the patient is a human.
39. (withdrawn-original) The method of Claim 29 wherein the ischemic event is transient.
40. (withdrawn-original) The method of Claim 29 wherein the ischemic event is acute.
41. (withdrawn-original) The method of Claim 29 wherein the ischemic event is stroke, head trauma, spinal trauma, general anoxia, or hypoxia.
42. (withdrawn-original) The method of Claim 29 wherein the ischemic event occurs during cranial hemorrhage, perinatal asphyxia, cardiac arrest or status epilepticus.
43. (withdrawn-original) A method of inhibiting post-ischemic vascular permeability of cerebral blood vessels in a patient suffering from a cerebrovascular event comprising administering a therapeutically effective amount of a compound of the formula



wherein:

X is N, CH


n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, and pharmaceutically acceptable salts thereof; with the proviso that when n is 1, X is not N.

44. (withdrawn-original) The method of Claim 43 wherein R' is methyl.
45. (withdrawn-original) The method of Claim 43 wherein R is methyl or ethyl.

46. (withdrawn-original) The method of Claim 43 wherein X is N.
47. (withdrawn-original) The method of Claim 43 wherein X is CH.
48. (withdrawn-original) The method of Claim 43 wherein the compound is:  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-  
3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[3-(4-ethyl-1-piperazinyl)propoxy]- 6-methoxy-3-  
quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-  
quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 7-[2-(4-ethyl-1-piperazinyl)ethoxy]- 6-methoxy-3-  
quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-  
quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-  
quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-  
yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-  
methoxyquinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-  
yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-  
yl)methoxy]quinoline-3-carbonitrile; 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-  
(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-  
yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-  
piperazinyl)ethoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-  
yl)ethoxy]quinoline-3-carbonitrile; or  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-  
3-quinolinecarbonitrile; and pharmaceutically acceptable salts thereof.
49. (withdrawn-original) The method of Claim 43 wherein compound is administered  
between about 6 to about 24 hours after the ischemic event.

50. (withdrawn-original) The method of Claim 43 wherein the therapeutically effective amount is from about 1 mg/kg to about 30 mg/kg.
51. (withdrawn-original) The method of Claim 43 comprising administering compound of Formula I intravenously.
52. (withdrawn-original) The method of Claim 43 wherein the patient is a human.
53. (withdrawn-original) The method of Claim 43 wherein the ischemic event is transient.
54. (withdrawn-original) The method of Claim 43 wherein the ischemic event is acute.
55. (withdrawn-original) The method of Claim 43 wherein the ischemic event is stroke, head trauma, spinal trauma, general anoxia, or hypoxia.
56. (withdrawn-original) The method of Claim 43 wherein the ischemic event occurs during cranial hemorrhage, perinatal asphyxia, cardiac arrest or status epilepticus.
57. **(currently amended)** A compound having the structure:



[[I]]

wherein:

n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, **[[and]] or a** pharmaceutically acceptable **[[salts]] salt** thereof.

58. **(currently amended)** A compound of Claim 57 **or a pharmaceutically acceptable salt thereof** wherein R' is methyl.

59. **(currently amended)** A compound of Claim 57 **or a pharmaceutically acceptable salt thereof** wherein R is methyl or ethyl.

60. **(currently amended)** A compound which is:

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;


4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile; or

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile; **[[and]] or a pharmaceutically acceptable [[salts]] salt thereof.**

61. **(currently amended)** A pharmaceutical composition comprising a compound having the structure



**[(I)]**

wherein:

n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, **[[and]] or a** pharmaceutically acceptable **[[salts]] salt** thereof; and a pharmaceutically acceptable carrier or excipient.

62. **(currently amended)** A pharmaceutical composition of Claim 61 comprising a compound which is:

4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;


4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]- 6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile;

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile; or

4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile; **[[and]] or a** pharmaceutically acceptable **[[salts]] salt** thereof.

63. **(currently amended)** A pharmaceutical composition comprising a vascular permeability inhibiting amount of a compound having the structure:



**[[1]]**

wherein:

X is **[[N,]]** CH<sub>2</sub>;

n is an integer from 1-3; and

R' and R are independently, alkyl of 1 to 3 carbon atoms, **[[and]] or a** pharmaceutically acceptable **[[salts]] salt** thereof, ~~with the proviso that when n is 1, X is not N,~~ and a pharmaceutical carrier or excipient.

64. **(currently amended)** A pharmaceutical composition of Claim 63 comprising a compound which is :

~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;~~  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[3-(4-ethyl-1-piperazinyl)propoxy]-6-methoxy-3-quinolinecarbonitrile;~~  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-3-quinolinecarbonitrile;~~  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[2-(4-ethyl-1-piperazinyl)ethoxy]-6-methoxy-3-quinolinecarbonitrile;~~  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]-3-quinolinecarbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile;  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-7-[(1-ethylpiperidin-4-yl)methoxy]-6-methoxyquinoline-3-carbonitrile;  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;~~  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinoline-3-carbonitrile;  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(4-ethylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile;~~  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[3-(1-methylpiperidin-4-yl)propoxy]quinoline-3-carbonitrile; **or**  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]quinoline-3-carbonitrile;~~  
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-ethoxy-7-[2-(1-methylpiperidin-4-yl)ethoxy]quinoline-3-carbonitrile; **[[or]]**  
~~4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-propyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;~~ **[[and]]** **or a** pharmaceutically acceptable **[[salts]] salt** thereof.

65. (original) The composition of Claim 63 in an intravenous dosage form.